Media Thread, page-7461

Yuman mentioned the Ph1 would likely commence early to middle of next year. These things seem to always start later than expected so I’m anticipating a mid year kick off.

It was spoken about yesterday afternoon that the onCARlytics pre-clinical work showed a very quick and near 100% result when onCARlytics was combined with a CD19 targeting therapy. I expect they’ll know pretty quick if it works and the only hold up will be constraints on how quick regulatory authorities allow them to progress.

I’m expecting a significant inflexion point from the science side of things by the end of next year… and hopefully it will be that it works as believed. It’s anyones guess what the share price will do but the science certainly appears to progressing well.